Jackie Beltrani Joins Cosette Pharmaceuticals as Director, Commercial Operations.

We are pleased to announce that Jackie Beltrani has joined Cosette Pharmaceuticals as Director, Commercial Operations. Jackie will report to Kian Kazemi and will be based in the Bridgewater office.

Read More

Cosette Pharmaceuticals Launches Betaine Anhydrous Powder, AB-rated to Cystadane® (betaine anhydrous for oral solution)

Apurva Saraf, President and CEO of Cosette, stated "This launch is further evidence of Cosette’s ability to partner globally and bring important drugs to the market, and furthers our transformation into a specialty pharmaceutical company.  We stay true to our firm belief of Innovating Every Day, to be a trusted partner of choice, and to continue the important work of serving U.S. patients and prescribers.”

Read More

Cosette Pharmaceuticals Announces the Approval and Launch of Metronidazole Gel USP, 1%.

Cosette Pharmaceuticals, Inc ("Cosette") announced that the U.S. Food and Drug Administration (FDA) has approved the Abbreviated New Drug Applications (ANDA) for Metronidazole Gel USP, 1%.

Read More

Cosette Pharmaceuticals Announces the launch of Griseofulvin Oral Suspension, 125 mg/5 mL.

Cosette Pharmaceuticals, Inc began shipping Griseofulvin Oral Suspension, 125 mg/5 mL (0713-0850-04) into all channels in the United States.

Read More

Cosette Pharmaceuticals Appoints Kevin Hickey, Vice President, Brand Sales and Marketing to Accelerate Transformation

“We are very excited to have Kevin Hickey join our team. His tremendous experience in strategy and execution of branded products will be instrumental as we integrate our eight cardio branded products through our transformative acquisition from Daiichi Sankyo and get ready for the imminent launches of several new products and lifecycle management strategies.” said Apurva Saraf, President and CEO, Cosette Pharmaceuticals.

Read More

Cosette Pharmaceuticals Announces the Approval and Launch of First Generic Versions of TAZORAC® (tazarotene) gel, 0.05% and 0.1%, with 180 days Competitive Generic Therapy (CGT) exclusivity

Cosette announced that the U.S. Food and Drug Administration (FDA) has approved the Abbreviated New Drug Applications (ANDA) for the first generic versions of TAZORAC® (tazarotene) gel, 0.05% and 0.1%, with 180 days Competitive Generic Therapy (CGT) exclusivity. Cosette has already commenced commercial shipments, triggering the 180 days exclusivity.

Read More

Ganesh Pillarisetti has joined Cosette Pharmaceuticals as Vice President, IT

Ganesh Pillarisetti has joined the executive team as Vice President, IT at Cosette Pharmaceuticals. Ganesh will report to our President and CEO, Apurva Saraf, and will be based out of our office at South Plainfield, New Jersey. In this critical role, Ganesh's expertise in leveraging IT to streamline processes to increase both efficacy and efficiencies in our core areas of manufacturing, supply chain, quality, finance etc. will help us strongly deliver on our growth strategy of inorganic and organic growth through relentless execution.

Read More

Cosette Pharmaceuticals Appoints Rick Casten as CFO Amid Transformational Growth

Bridgewater, NJ. July 6, 2022. Cosette Pharmaceuticals, Inc., a New Jersey-based specialty pharmaceutical company, today announced the appointment of Rick Casten as Chief Financial Officer (CFO), bolstering its executive leadership team.

Read More